A Century‑Old TB Shot May Hold the Key to Reversing Type 1 Diabetes

Imagine a vaccine that’s been around since the 1920s suddenly turning up on the front lines of a modern battle against type 1 diabetes. That’s exactly what a team of researchers from Stanford University announced last month, and it’s already causing a buzz in labs and on patient forums alike.

What they used wasn’t a brand‑new drug, but the Bacillus Calmette‑Guérin (BCG) vaccine – the same shot doctors have been giving for a century to protect against tuberculosis. The twist? In a small, carefully monitored clinical trial, a handful of adults with long‑standing type 1 diabetes saw their blood‑sugar numbers improve dramatically after receiving the vaccine.

Here’s the gist of what happened. The volunteers were given two doses of BCG, spaced a few months apart. Over the next year, their hemoglobin‑A1c levels – the gold‑standard marker for average blood glucose – dropped from the high‑90s down into the 70s, edging closer to normal ranges. Even more striking, some participants who had stopped insulin injections for years found they could manage their glucose without daily shots.

So, what’s the science behind this unexpected turn? The researchers say the answer lies in how BCG reshapes the immune system and the way cells process sugar. First, the vaccine appears to dial down the rogue autoimmune attack that normally destroys the pancreas’s beta cells – the very cells that make insulin. By nudging certain immune cells (like regulatory T‑cells) into a more tolerant mode, BCG reduces the inflammation that keeps the pancreas under siege.

Second, and perhaps more intriguingly, BCG seems to flip a metabolic switch in the body’s cells. In healthy people, glucose is mostly burned via oxidative phosphorylation – a high‑efficiency process that uses oxygen. In type 1 diabetes, cells shift toward a less efficient form of sugar burning called glycolysis, which actually helps preserve beta‑cell function. The vaccine revives this glycolytic pathway, prompting cells to use glucose in a way that encourages the regeneration of insulin‑producing cells.

“It’s like we’re giving the body a gentle reboot,” explains Dr. Denise Faustman, the study’s senior author. “Instead of trying to add more insulin from the outside, we’re coaxing the body to start making its own again.”

The findings are still early‑stage, and the trial involved just 20 participants, but the magnitude of the effect has drawn attention from both the scientific community and patient advocacy groups. If larger studies confirm these results, BCG could become the first therapy that actually restores pancreatic function rather than merely replacing what’s lost.

Of course, there are plenty of questions left unanswered. How long does the benefit last? Does the vaccine work equally well in children, who make up the majority of new type 1 diagnoses? And what about safety – can a vaccine designed for TB cause unforeseen side‑effects when repurposed for a chronic autoimmune disease?

So far, BCG’s safety profile remains solid. The vaccine has been administered to billions of people worldwide, and serious adverse reactions are rare. In the Stanford trial, the most common side‑effects were mild flu‑like symptoms that faded within a few days.

Looking ahead, the researchers plan a multicenter phase‑II trial that will enroll a few hundred participants across the United States and Europe. They hope to fine‑tune the dosing schedule, determine the optimal timing for repeat shots, and track how long the metabolic reprogramming persists.

For patients living with type 1 diabetes, the prospect of a treatment that could someday lessen or even eliminate the need for daily insulin is nothing short of hopeful. “It’s still early days,” cautions Dr. Faustman, “but the idea that a century‑old vaccine could help us rewrite the story of an autoimmune disease is incredibly exciting.”

Until larger studies arrive, doctors are unlikely to prescribe BCG off‑label for diabetes, but the conversation it has sparked underscores a broader trend: repurposing old medicines for new challenges. In a world where novel drug development can take over a decade and cost billions, finding hidden potential in existing therapies may be one of the smartest ways forward.

Whether BCG ultimately earns a place in the diabetes toolkit remains to be seen, but the study has already reminded us that medical breakthroughs sometimes come from looking at familiar tools with fresh eyes.